Anchored in research undertaken by Skyran Biologics Inc principals at Penn State Collee of Medicine, the firm is addressing use of eye-drops - versus intralocular injections - for those suffering from diabetic retinopathy. Within 20 years of a Type 1 Diabetes diagnosis, almost all patients will have damage to the retina of the eye potentially leading to blindness with some 60% of patients diagnosed with Type 2 Diabetes over that period also having some form of Diabetic Retinopathy. Overall this represents some 8M Americans. Typically, treatment involves monthly jcetion directly into the eye. However, current therapies cannot be used in the early stages of the disease and in many patients, the traetments fail. Preliminay data from the work of the principals of Skyran Biologics suggest that their rproprietary PEDF derived peptides could be a platform therapeutic for other ophthalmic degenerative diseases.